Fundraising FoxWindgap Medical
Watertown, US · Founded 2011 · Delaware corporation · 8 known investors
Find your way into Windgap Medical
Sign up to see every warm intro you have to Windgap Medical
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Windgap Medical team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Windgap Medical develops and commercializes drug-device combination products, including a dual-chamber autoinjector technology for administering complex injectable medications. Serving the pharmaceutical and healthcare market, the company focuses on simplifying and automating drug delivery with an emphasis on sustainability.
Founders & leadership
Windgap Medical was founded in 2011 by Brent Buchine.
BB
Brent BuchineCo-Founder and Chief Business Officer (CBO)Brent Buchine holds a Ph.D. in materials science and has spent over 20 years in life sciences and semiconductor sectors, including founding or co-founding multiple companies and serving as CTO, interim CEO, and Chief Business Officer at Windgap Medical.
AM
Aaron MannChief Executive OfficerHe previously served as CEO of Kindeva Drug Delivery, a contract manufacturer for biopharmaceutical companies spun from 3M in 2020, and held leadership roles at 3M's Drug Delivery Systems division and Phillips-Medisize; he also worked at Bain & Company and earned degrees from Harvard Business School and Carleton College.
JD
Jason DurkinVice President Supply ChainJason Durkin is an executive with background in medical devices and combination products, including experience in product development, technical sales, marketing, business development, and portfolio management.
JC
John CadiganAdvisor, Board Observer, InvestorJohn Cadigan brings over 30 years of medical device and software development experience, having held VP and general management roles at companies including Philips Healthcare, Hewlett Packard, and Data General. He holds a Bachelor's degree in Computer Science from the University of Lowell and completed pre-med requirements at Harvard University Extension School.
AW
Anthony WatsonVice President Regulatory Affairs and QualityAnthony Watson is an Executive Officer at Windgap Medical with over 25 years of regulatory affairs experience in the medical device and pharmaceutical industries, including leadership roles at the FDA and biotech/biopharma companies. He holds a degree from the Naval Academy and graduate degrees in business administration and management information systems.
CS
Christopher StepanianNamed on SEC filing
Board
RR
Richard RussellBoard director
TK
Timothy KrochukBoard director
JR
John Reading WilsonBoard director
JC
JM
J. Melville EngleBoard director
Investors · 8
Bantam Grouplisted by Bantam GroupWestwood
How we know: the VCSheet dataset · Not right? Tell us
Boston Harbor Angelslisted by Boston Harbor AngelsBoston · $250K – $1.5M
How we know: Boston Harbor Angels's portfolio page · Not right? Tell us
Colle Capital Partnerslisted by Colle Capital PartnersNew York · $500K – $2M
How we know: Colle Capital Partners's portfolio page · Not right? Tell us
Launchpad Venture Grouplisted by Launchpad Venture GroupBoston · $8M – $10M
How we know: the VCSheet dataset · Not right? Tell us
Cobro VenturesreportedMclean
How we know: windgapmedical.com · Not right? Tell us
Taiwania CapitalreportedTaipei
How we know: funding news · windgapmedical.com · Not right? Tell us
Also in the syndicate · 2
Molex VenturesShepherd Kaplan Krochuk
Reported raises · per SEC filings
Form D private placements$77M disclosed across 9 rounds · 2014–2023
▶$12.7MraisedJan 2026 · 13 investors · PharmaceuticalsRule 506(b)
▶$12.7MraisedJan 2026 · 13 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Max MeehanExecutive Officer
- Richard RussellDirector
- Brent BuchineDirector
- Timothy KrochukDirector
- Aaron MannExecutive Officer, Director
- Jason DurkinExecutive Officer
- John CadiganExecutive Officer
- Anthony WatsonExecutive Officer
- John Reading WilsonDirector
- Offering amount
- $17.3M
- Amount sold
- $12.7M
- First sale
- Nov 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$39.2MraisedJan 2022 · 46 investors · PharmaceuticalsRule 506(b)
▶$39.2MraisedJan 2022 · 46 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Michael HuangDirector
- Richard RussellDirector
- John Reading WilsonDirector
- Christopher StepanianExecutive Officer, Director
- Brent BuchineExecutive Officer, Director
- John ConleyDirector
- Offering amount
- $42.2M
- Amount sold
- $39.2M
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$360.5KraisedMar 2020 · 20 investors · PharmaceuticalsRule 506(b)
▶$360.5KraisedMar 2020 · 20 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Brent BuchineExecutive Officer, Director
- Christopher StepanianExecutive Officer, Director
- J. Melville EngleDirector
- John ConleyDirector
- Tim KrochukDirector
- John Reading WilsonDirector
- Richard GabrielDirector
- Offering amount
- $2M
- Amount sold
- $360.5K
- First sale
- Feb 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$12.2MraisedJan 2019 · 106 investors · PharmaceuticalsRule 506(b)
▶$12.2MraisedJan 2019 · 106 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- John Reading WilsonDirector
- Richard GabrielDirector
- John ConleyDirector
- J. Melville EngleDirector
- Tim KrochukDirector
- Brent BuchineExecutive Officer, Director
- Christopher StepanianExecutive Officer, Director
- Offering amount
- $39M
- Amount sold
- $12.2M
- First sale
- Jan 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.8MraisedJul 2018 · 75 investors · PharmaceuticalsRule 506(b)
▶$3.8MraisedJul 2018 · 75 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Richard GabrielDirector
- J. Melville EngleDirector
- Tim KrochukDirector
- Christopher StepanianExecutive Officer, Director
- Brent BuchineExecutive Officer, Director
- John ConleyDirector
- Offering amount
- $4M
- Amount sold
- $3.8M
- First sale
- May 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.9MraisedApr 2016 · 46 investors · PharmaceuticalsRule 506(b)
▶$2.9MraisedApr 2016 · 46 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Christopher StepanianExecutive Officer, Director
- Richard GabrielDirector
- Tim KrochukDirector
- J. Melville EngleDirector
- John ConleyDirector
- Brent BuchineExecutive Officer, Director
- Offering amount
- $4M
- Amount sold
- $2.9M
- First sale
- Mar 2016
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
▶$4.2MraisedAug 2015 · 92 investors · PharmaceuticalsRule 506(b)
▶$4.2MraisedAug 2015 · 92 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- John ConleyDirector
- Richard GabrielDirector
- Brent BuchineExecutive Officer, Director
- Christopher StepanianExecutive Officer, Director
- Tim KrochukExecutive Officer
- J. Melville EngleDirector
- Offering amount
- $4.5M
- Amount sold
- $4.2M
- Minimum investment
- $4.2K
- Proceeds to insiders
- $465K
- First sale
- May 2015
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
▶$250KraisedMay 2015 · 1 investors · PharmaceuticalsRule 506(b)
▶$250KraisedMay 2015 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- J. Melville EngleDirector
- Tim KrochukDirector
- John ConleyDirector
- Richard GabrielDirector
- Brent BuchineExecutive Officer, Director
- Christopher StepanianExecutive Officer, Director
- Offering amount
- $250K
- Amount sold
- $250K
- Minimum investment
- $250K
- First sale
- May 2015
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as Windgap Medical.
In the news
Frequently asked questions
- What does Windgap Medical do?
- Windgap Medical develops and commercializes drug-device combination products, including a dual-chamber autoinjector technology for administering complex injectable medications. Serving the pharmaceutical and healthcare market, the company focuses on simplifying and automating drug delivery with an emphasis on sustainability.
- Who founded Windgap Medical?
- Windgap Medical was founded by Brent Buchine in 2011.
- Who are Windgap Medical's investors?
- Windgap Medical's investors include Bantam Group, Boston Harbor Angels, Colle Capital Partners, Launchpad Venture Group, Cobro Ventures, Taiwania Capital.
- How much funding has Windgap Medical raised?
- Windgap Medical has disclosed $77M raised across 9 rounds.
- Where is Windgap Medical headquartered?
- Windgap Medical is headquartered in Watertown, US.